Nestlé Skin Health has a range of medical and consumer brands through three complementary business units, including Epiduo and Soolantra in prescription, Restylane and Azzalure in aesthetics, Cetaphil and Proactiv in Consumer Care.
According to the company, consumer skin care represents 35% of sales, aesthetics 34% and prescription 31%.
Headquartered in Lausanne, Switzerland, Nestlé Skin Heath employs more than 5,000 people across 40 countries. With R&D capabilities and manufacturing facilities spread across the globe, Nestlé Skin Health had sales of around CHF 2.7 billion in 2017, or approximately $2.8 billion.
“Nestlé Skin Health has made significant progress under its new leadership team over the past two years. The company has developed convincing growth strategies for each of its business units and regained a competitive cost structure. Now is the right time to explore the best ownership structure for Nestlé Skin Health and to consider ways of taking it to the next level,” said Mark Schneider CEO.
The company said the review is expected to be completed by mid-2019.